Introduction
============

Major depressive disorder (MDD), a severely debilitating mental disease, negatively affects the quality of life of a substantial percentage of the world population, and is associated with a lifetime morbidity of 4.4--20% ([@b1-mmr-17-01-0093]). It is predicted that MDD will be the second most common illness in 2020, according to the 1990 Global Burden of Illness list. It is estimated that the economic burden of depression was \$52.9 billion in 1990 and \$83.1 billion in 2000 in the United States ([@b2-mmr-17-01-0093],[@b3-mmr-17-01-0093]). Therefore, much attention has been given to depression research worldwide. Over the last few decades, many pathogenetic mechanisms have been put forward for MDD ([@b4-mmr-17-01-0093]). However, the molecular mechanisms of MDD remain largely unknown. It is therefore urgent to elucidate the underlying mechanisms of MDD.

To gain insight into the pathogenesis of depression, our team previously used a proteomics approach on human plasma. However, the differential proteins in Xu *et al* ([@b5-mmr-17-01-0093]) were different from those in Yang *et al* ([@b6-mmr-17-01-0093]) and Song *et al* ([@b7-mmr-17-01-0093]). A possible reason for the lack of concordance is variability in the factors that cause depression. The pathogenesis of depression may therefore differ among patients, accounting for the varying proteomic changes. Furthermore, some patients might have taken antidepressants that affect the metabolism of proteins in plasma ([@b8-mmr-17-01-0093]). Therefore, we established a mouse model of chronic unpredictable mild stress (CUMS) to acquire more robust data ([@b9-mmr-17-01-0093]). In this model, mice in the CUMS group are exposed to the same stressors at the same time. Both physical and mental stressors are given to imitate the risk factors that depressive patients encounter in daily life. Hence, the CUMS model might well mimic human depression, and plasma from CUMS mice might help clarify the molecular changes in the disease.

MDD is a mental illness, and therefore, cerebrospinal fluid (CSF) and brain tissue samples might be better for proteomic studies investigating the molecular mechanisms of MDD; however, such samples are not practically accessible for living human subjects. In contrast, plasma samples can be obtained easily. Moreover, the pathogenesis of depression involves several brain regions, while most published papers only examine one region at a time ([@b10-mmr-17-01-0093]--[@b12-mmr-17-01-0093]). CSF, plasma and brain tissue exchange their molecular components through the blood-brain and CSF-brain barriers, which suggests that some proteins might be exchanged between the central nervous system and the peripheral circulation ([@b13-mmr-17-01-0093],[@b14-mmr-17-01-0093]). Therefore, plasma samples might be better for examining the pathogenesis of depression ([@b15-mmr-17-01-0093]).

Proteomics is a hypothesis-free approach, and it is a useful tool for discovering novel molecules involved in the pathogenesis of disease. It has been applied in a wide range of diseases, such as depression, schizophrenia and other psychiatric illnesses ([@b16-mmr-17-01-0093]). In the present study, isobaric tags for relative and absolute quantitation (iTRAQ) was employed for identifying proteins differentially expressed between CON and CUMS mice. Furthermore, some of the proteins involved in the significantly changed pathways were validated by western blotting.

Materials and methods
=====================

### Animals

A total of 40 adult male mice (8--10 weeks of age) were bought from Chongqing Medical University\'s animal facility. Unless indicated otherwise, the mice were maintained under standard conditions (12h-12 h light-dark cycle, lights on from 07:00 a.m. to 07:00 p.m.; temperature: 23±1°C; relative humidity of 40--60%; food and water available *ad libitum*). Chongqing Medical University\'s Ethics Committee approved all procedures, which were in accordance with the National Institutes of Health\'s Animal Research Guide. Efforts were made to reduce the number of deaths and to minimize suffering. ([@b9-mmr-17-01-0093]).

### CUMS protocol

The CUMS protocol was carried out according to our previously published papers, with some minor modifications. After adaptation and sucrose preference training, each lasting a week, mice were isolated into two groups: CUMS group (*n*=20) and CON group (*n*=20). The mice in the CUMS group were subjected to various repeated unpredictable mild stressors for 4 weeks, during which the sucrose preference test was performed. Minor stress sources included deprivation of water and food, paired housing, wet bedding, 45° cage tilt, night lighting, white noise, strobe, and odor exposure. All stressors were applied in a random order, and we did not repeat the same stressors over 2 consecutive days.

### Behavioral test

The sucrose preference test (SPT) is one of the most important tests for evaluating depressive symptoms in mice. After 1 week of adaptation to the environment, each mouse was trained using two bottles of water for 1 week, one with 1% sucrose solution and the other with tap water. According to the baseline of sucrose preference, the mice were segregated into two groups with no significant difference. One group was exposed to CUMS stressors, while the other group was kept under standard conditions. Sucrose preference was measured starting at 8 am every Sunday morning for 24 h. During the test, the mice were placed in separate cages with equal access to the two bottles. The location of the two bottles was changed randomly to avoid position preference. The total weight consumed by the mouse was measured. Sucrose preference (SP) was calculated as follows: SP=(weight of 1% sucrose solution consumed/\[the weight of 1% sucrose solution consumed + the weight of water consumed\]) × 100%.

Open field testing was used to assess space exploration behavior. Before the test, the mice were placed in the experimental room for 30 min. The experiment was carried out in a soundproof room from 8 am to 1 pm. Only one mouse was placed in the open field test apparatus (44.5×44.5×45 cm) at a time, and allowed to freely explore the field for 6 min. The behavior was recorded and analyzed with an automatic video-tracking system (Smart, Panlab SL, Barcelona, Spain). The box was thoroughly cleaned with alcohol after each trial.

The forced swim test, also known as the behavioral despair test, which evaluates the rodent\'s response to the threat of drowning, was carried out in the experimental room from 8 am to 1 pm. In a separate test, the mouse was placed in the apparatus (height, 30 cm; diameter, 15 cm) for 5 min, and the pool was filled with tap water. The depth of the water was about 15 cm, and the water temperature was about 23±1°C. After each trial, the water was replaced with fresh water. Behavioral recording and analysis were performed using the Smart system mentioned above.

### Immunodepletion of high abundance plasma proteins

Frozen plasma samples from the two groups (CON (*n*=20) and CUMS (*n*=20) were thawed, and equal-volume samples from six or seven mice ([@b6-mmr-17-01-0093],[@b7-mmr-17-01-0093]) for each group were pooled to minimize the effect of individual variation (each group therefore generated three pooled samples). The pooled plasma samples were immunodepleted of high abundance plasma proteins using a Multiple Affinity Removal LC Column-Mouse 3 (Agilent Technologies, Inc., Santa Clara, CA, USA). The procedure was carried out according to the manufacturer\'s instructions. To evaluate the removal of high abundance proteins, samples of non-immunodepleted plasma and immunodepleted plasma were separated on 12.5% SDS-PAGE gels and then stained with Coomassie Blue ([@b5-mmr-17-01-0093],[@b17-mmr-17-01-0093]).

### iTRAQ labeling, and strong cation exchange (SCX) fractionation

After removal of high abundance proteins from plasma, the samples were quantified using the BCA assay. Then, 300-µg samples of total protein for each group were taken out for analysis. To these samples, 25 µl of SDT solution was added, and then DTT solution to a final concentration of 100 mM. These samples were then placed in a boiling water bath for 5 min and then cooled to room temperature. Thereafter, 200 µl of UA buffer (8 M urea, 150 mM Tris-HCl, pH 8.0) was added, and the samples were then centrifuged at 14,000 × g for 30 min in a 30-kd ultrafiltration centrifuge tube. Subsequently, 200 µl of UA buffer was added to the samples and centrifuged at 14,000 × g for 30 min. After discarding the filtrate, 100 µl of IAA (50 mM IAA in UA) was added. The solution was shaken at 600 rpm for 1 min, followed by a 45 min incubation at room temperature. The samples were then centrifuged at 14,000 × g for 30 min. Thereafter, 100 µl of UA buffer was added to the concentrate and centrifuged at 14,000 × g, twice, 30 min each. After discarding the filtrate, 100 µl of 25 mM ABC was added, and the solution was centrifuged at 14,000 × g for 30 min. After discarding the filtrate, 40 µl of trypsin buffer (6 µg trypsin in 40 µl 100 mM ABC) was added. This solution was shaken at 600 rpm for 1 min followed by a 16-18-hour incubation at 37°C. Then, 40 µl of 25 mM ABC was added to the previous solution and centrifuged at 14,000 × g for 30 min. Subsequently, 0.1% TFA solution was added, and the OD~280~ was measured after desalting on a C18 cartridge (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). Samples containing 100 µg of protein were labeled with the AB kit (iTRAQ Reagent-8plex Multiplex kit (AB Sciex, Foster City, CA, USA) according to the manufacturer\'s protocol (113, 114, 115 for the CON group; 116, 117, 118 for the CUMS group). The parameters used for SCX fractionation were as follows: AKTA Purifier 100 (GE Healthcare, Chicago, IL, USA), polysulfoethyl 4.6×100 mm column (5 µm, 200 Å) (PolyLC Inc., Columbia, MD, USA), SCX Buffer A (10 mM KH~2~PO~4~ pH 3.0, 25% CAN), SCX Buffer B (10 mM KH~2~PO~4~ pH 3.0, 500 mM KCl, 25% CAN). The peptide fragments after iTRAQ labeling were mixed and subjected to SCX fractionation. For each test, 33 fractions were collected from each group and then combined into ten pools according to the SCX chromatogram, which were next desalted with a C18 cartridge (66872-U; Sigma-Aldrich; Merck KGaA) ([@b9-mmr-17-01-0093]).

### Liquid chromatography-tandem mass spectrometry

Each sample was separated using a nano-flow velocity HPLC liquid system, Easy nLC (Thermo Fisher Scientific, Inc., Waltham, MA, USA), and 0.1% formic acid aqueous solution (buffer A) and 0.1% formic acid acetonitrile aqueous solution (acetonitrile 84%) (buffer B) were used in the experiment. The column was equilibrated with 95% buffer A. Then, samples were loaded with the autosampler onto the Thermo Scientific EASY-column (2 cm ×100 µm, 5 µm-C18) and separated on an analytical column (Thermo Scientific EASY-column, 75 µm × 100 mm, 3 µm-C18) at a flow rate of 300 nl/min. The liquid phase parameters were as follows: 0 to 55 min, buffer B from 0 to 50% with a linear gradient; 55 to 57 min, buffer B from 50 to 100% with a linear gradient; 57 to 60 min, buffer B maintained at 100%. After separation by capillary high performance liquid chromatography, each sample was analyzed by mass spectrometry using a Q-Exactive mass spectrometer (Thermo Finnigan, San Jose, CA, USA). The parameters were as follows: Analysis time, 60 min; detection method, positive ion; parent ion scanning range, 300--1,800 m/z; primary mass spectrometry resolution, 70,000 at m/z 200; AGC target, 3e6; primary maximum IT, 10 ms; number of scan ranges, 1; dynamic exclusion, 40.0 s. The mass/charge ratio of the fragments of the polypeptide and polypeptide were collected using the following parameters: MS2 activation type, HCD; isolation window, 2 m/z; secondary mass spectrometry resolution, 17,500 at m/z 200; microscans, 1; secondary maximum IT, 60 ms; normalized collision energy, 30 eV; underfill ratio, 0.1%. Subsequently, the original data was processed with Mascot 2.2 and Proteome Discoverer 1.4 software packages (Thermo Fisher Scientific, Inc.) for identification and quantitative analysis. The database was downloaded from Unipart (uniprot_mouse_78469_20150825.fasta, including 78649 series, downloaded on 2015-07-25). Peptide FDR was set at ≤0.01 ([@b9-mmr-17-01-0093]).

### Ingenuity pathway analysis (IPA)

IPA software has been widely used in proteomics research ([@b9-mmr-17-01-0093],[@b11-mmr-17-01-0093]). To determine the significant canonical pathways, networks of interacting proteins and models of functions and diseases, we uploaded the differentially expressed protein lists (with UniProt accession) and the directions of change of these proteins onto the IPA server (Qiagen, Inc., Valencia, CA, USA). All these analyses used Fisher\'s exact test with a P\<0.5.

### Western blotting

Frozen plasma samples were thawed and diluted 50 times using 1X PBS and 1X loading buffer. The volume of the loading buffer was one-fourth of the total volume. The proteins were denatured at 100°C for 10 min. Following SDS-PAGE, the proteins were transferred to PVDF membranes. After blocking in 5% non-fat milk power in TBST for 2 h at room temperature, the PVDF membrane was incubated for 10 h at 4°C with the following primary antibodies: Anti-lipopolysaccharide binding protein (LBP) antibody (1:500; Ruiying Biological, <http://www.rlgene.com/>), anti-fibrinogen β chain (FGB) antibody (1:1,000; Sangon Biotech Co., Ltd., Shanghai, China), anti-α-1 antitrypsin (SERPINA1) antibody (1:1,000; Abcam, Cambridge, UK), anti-complement factor H antibody (CFH) (1:500; Abcam). After three washes with THST, the membrane was incubated with anti-sheep or anti-rabbit secondary antibody (1:10,000) at room temperature for 2 h, and then the membrane was washed another three times with TBST (10 min each). The relative intensity of each protein was calculated with Quantity One software (version 4.6.7; Bio-Rad Laboratories, Inc., Hercules, CA, USA).

### Statistical analysis

All of the data results were presented as mean ± standard deviation. Analysis of sucrose preference and body weight of mice was performed using ANOVA method. Behavioral data of the two groups of mice and the data of western blotting were analyzed by Student\'s t-test. All data shown in this study were calculated by SPSS21.0 (IBM Corp., Armonk, NY, USA) used in our previous study. The threshold for statistical significance was set at P\<0.05.

Results
=======

### Assessment of the CUMS mouse model

The CUMS mouse model was evaluated using the sucrose preference test (SPT), body weight measurement, the forced swim test (FST), and the open-field test (OFT). Given that the plasma samples used in this study were collected from the same batch of mice used in our previous publication ([@b9-mmr-17-01-0093]), the results are only briefly described here. Body weight in the CUMS group was significantly lower than in the CON group after treatment (P=0.001). The total distance traveled was not significantly different at baseline, but was significantly shortened after 28 days of CUMS (P\<0.05). Compared to the CON group, immobility time was significantly increased (P\<0.05) and sucrose preference was significantly lower in the CUMS group in the last week (P\<0.05).

### Immunodepletion of high-abundance proteins

To assess the efficacy of depletion, equal amounts of sample from each group were loaded onto a one-dimensional electrophoresis gel. After electrophoresis, the gel was stained with Coomassie Blue. More protein bands appeared after immunodepletion comparing with crude plasma samples ([Fig. 1](#f1-mmr-17-01-0093){ref-type="fig"}). This indicates that immunodepletion is an appropriate method for concentrating low abundance proteins.

### Plasma analysis by iTRAQ-based quantitative proteomics

To identify differentially expressed proteins in CUMS mice compared with CON mice, 2D LC-MS/MS coupled with iTRAQ labeling was performed. As all samples from each group were mixed for experimentation, the main concern was systematic variation. It has been published that the iTRAQ approach for identifying and quantifying differentially expressed proteins on a large-scale entails at least a 30% technical variability ([@b18-mmr-17-01-0093]). Therefore, a 1.3-fold change and unique peptides ≥2 threshold was used, as in our earlier study ([@b5-mmr-17-01-0093]). Using this cut-off threshold, 47 proteins were found to be significantly differentially expressed between the CUMS group and the CON group. Among these 47 proteins, 22 were upregulated and the remainder were downregulated in the CUMS group ([Table I](#tI-mmr-17-01-0093){ref-type="table"}).

### IPA analysis of the differential proteins

To analyze the overall function of these 47 significantly expressed proteins, we uploaded them onto the IPA server. The top 5 canonical pathways were LXR/RXR activation, acute phase response signaling, FXR/RXR activation, complement system, and intrinsic prothrombin activation pathway ([Table II](#tII-mmr-17-01-0093){ref-type="table"}). Four proteins related to these significantly changed canonical pathways were chosen for western blot validation. Additionally, IPA identified the following top five diseases and functions: Cell-to-cell signaling and interaction, developmental disorder, organismal injury and abnormalities, hereditary disorder, and immunological disease ([Table III](#tIII-mmr-17-01-0093){ref-type="table"}).

### Validation of differential proteins by western blotting

Four significantly changed candidate proteins were chosen for validation using western blotting-lipopolysaccharide-binding protein, fibrinogen β chain, α-1 antitrypsin, and complement factor H. Compared with the CON group, α-1 antitrypsin and lipopolysaccharide-binding protein were upregulated (P\<0.05) ([Fig. 2](#f2-mmr-17-01-0093){ref-type="fig"}). In contrast, expression of fibrinogen β chain (P\<0.05) was significantly reduced in the CUMS group ([Fig. 2](#f2-mmr-17-01-0093){ref-type="fig"}). These findings are concordant with our iTRAQ results. However, the expression levels of complement factor H were not significantly changed as assessed by western blotting (P\>0.05) ([Fig. 2](#f2-mmr-17-01-0093){ref-type="fig"}), although they were significantly upregulated in CUMS mice by the iTRAQ method.

Discussion
==========

The systemic response triggered by local inflammation, which can be seen in acute and chronic inflammation, is called the acute phase response. The function of acute phase proteins include opsonization, capturing microbes, complement activation, neutralizing enzymes and modulating immune responses. The acute phase proteins validated in this study included LBP, SERPINA1 and FGB, which are involved in the acute phase response pathway ([Table II](#tII-mmr-17-01-0093){ref-type="table"}). LBP is used as a marker of a variety of inflammatory diseases and the development and prognosis of disease ([@b19-mmr-17-01-0093]). Furthermore, depression and inflammation are closely related ([@b20-mmr-17-01-0093]). LBP can also affect the innate immune function and Toll-like receptor 4 ([@b21-mmr-17-01-0093],[@b22-mmr-17-01-0093]), which are involved in the pathogenesis of depression ([@b23-mmr-17-01-0093]). Thus, LBP might be involved in the pathogenesis of depression. LBP is also associated with other psychiatric disorders, such as Parkinson\'s disease ([@b24-mmr-17-01-0093]), and therefore, LBP may be closely related to central nervous system functions. The concentration of SERPINA1 in the plasma of depressed patients is increased ([@b25-mmr-17-01-0093]), consistent with our results. SERPINA1 also has a relationship with the immune system, the apoptotic process and the inflammatory response ([@b26-mmr-17-01-0093]). The concentration of FGB is reduced in the platelets of depressed patients ([@b27-mmr-17-01-0093]), also consistent with our results. This suggests that FGB is closely related to the occurrence and development of depression. The plasma concentration of FGB is also abnormal in Rett syndrome ([@b28-mmr-17-01-0093]), and Rett syndrome is a unusual genetic postnatal neurological disease negatively affecting the grey matter of the brain. Thus, FGB may be closely related to central nervous system functions.

Retinoid X receptors (RXRs) are nuclear receptors that mediate the biological effects of retinoids. RXRα is the dimerization partner for the type II nuclear receptors that include the liver X receptor (LXR). The LXR is activated by oxysterol ligands and forms a heterodimer with RXR. After the heterodimer is formed, LXR initiates the transcription of the target gene by binding to the LXR response element. LXR/RXR are involved in lipid metabolism, the inflammatory response and cholesterol and bile acid metabolism ([@b29-mmr-17-01-0093]). Previous studies suggest that abnormalities in these processes lead to the development of depression ([@b9-mmr-17-01-0093],[@b20-mmr-17-01-0093]). The farnesoid X receptor (FXR) is a member of the nuclear receptor family and is a key player in many metabolic pathways. FXR is activated by bile acids and their intermediates, which thus serves as a sensor of bile acid levels. Along with the retinoid X receptor (RXR), FXR plays a key role in linking bile acid regulation with lipoprotein and lipid and glucose metabolism ([@b30-mmr-17-01-0093]). Energy metabolism is dysregulated in depressed patients and in the CUMS mouse model ([@b5-mmr-17-01-0093],[@b10-mmr-17-01-0093],[@b11-mmr-17-01-0093]). Perturbations of the LXR/RXR and FXR/RXR pathways may be involved in the development of depression ([@b31-mmr-17-01-0093],[@b32-mmr-17-01-0093]). In this study, according to the IPA, iTRAQ data and western blotting validation, LBP is involved in LXR/RXR activation ([Table II](#tII-mmr-17-01-0093){ref-type="table"}), in accordance with a previous study ([@b33-mmr-17-01-0093]). SERPINA1 is also related to the LXR/RXR and FXR/RXR pathways ([Table II](#tII-mmr-17-01-0093){ref-type="table"}). Thus, LBP and SERPINA1 might be responsible for the occurrence and development of MDD via LXR/RXR and FXR/RXR pathways.

According to IPA analysis and previous studies, LBP is also involved in IL-10 signaling ([@b34-mmr-17-01-0093]). FGB is related to the coagulation system, the extrinsic prothrombin activation pathway, and role of tissue factor in cancer ([@b35-mmr-17-01-0093]). SERPINA1 participates in the coagulation system ([@b36-mmr-17-01-0093]), atherosclerotic signaling ([@b37-mmr-17-01-0093]), and IL-12 signaling and production in macrophages ([Table II](#tII-mmr-17-01-0093){ref-type="table"}) ([@b38-mmr-17-01-0093]). This suggests that these pathways likely contribute to the development of depression.

The various changes in proteins and pathways in the CUMS model might ultimately lead to a depressive state. In this study, the first five significantly changed functions and diseases identified by IPA were cell-to-cell signaling and interaction, developmental disorder, organismal injury and abnormalities, hereditary disorder, and immunological disease ([Table III](#tIII-mmr-17-01-0093){ref-type="table"}). These results suggest that depression is also related to structural abnormalities in the central nervous system ([@b39-mmr-17-01-0093]) as well as intercellular interaction and signal transmission ([Fig. 3](#f3-mmr-17-01-0093){ref-type="fig"}). Therefore, synaptic neurotransmission might be perturbed in CUMS mice.

However, the expression levels of factor H were not significantly changed as assessed by western blotting, although they were significantly upregulated in CUMS mice by the iTRAQ method. A similar phenomenon has also been observed in other previous studies ([@b5-mmr-17-01-0093],[@b6-mmr-17-01-0093]). The variability of dynamic range between iTRAQ and western blotting and the internal differences related to the steps of iTRAQ coupled with tandem mass spectrometry approach and western blotting analysis may lead to this discrepancy.

These results suggest that the CUMS mouse model is a suitable model of depression, and that peripheral plasma samples can, at least to an extent, provide some biomarkers of depression. The three significantly differentially expressed proteins (FGB, SERPINA1, LBP) are worthy of further studies on the molecular mechanisms of depression.
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![SDS-PAGE was used to assess the efficiency of removal of high-abundance plasma proteins. 20 µg of crude plasma (without depletion), CUMS depleted plasma, CON depleted plasma and marker were separated on a 12.5% SDS-PAGE gel and stained with Coomassie Blue. CUMS, chronic unpredictable mild stress; CON, control.](MMR-17-01-0093-g00){#f1-mmr-17-01-0093}

![Western blotting validation results of lipopolysaccharide-binding protein (LBP) (P\<0.001 vs. CON), fibrinogen-β chain (FGB) (P=0.030 vs. CON), α-1 antitrypsin (SERPINA1) (P=0.033 vs. CON) and Factor H (P=0.910 vs. CON). All samples were validated in triplicate. A loading control was used for normalizing protein amounts. CUMS (n=6), chronic unpredictable mild stress; CON (n=6), control.](MMR-17-01-0093-g01){#f2-mmr-17-01-0093}

![The uploaded proteins involved in intercellular interactions and signaling are shown in this diagram produced by IPA. Green and red protein nodes represent decreased and increased levels, respectively, in the CUMS group. Each protein node is connected to the relevant disease and functional nodes. Nodes of diseases and functions in blue indicate predicted inhibition, while those in yellow indicate predicted activation. The deeper the color, the stronger the activity. Arrows in red point to the proteins validated in this study.](MMR-17-01-0093-g02){#f3-mmr-17-01-0093}

###### 

Significant differentially expressed proteins identified by an iTRAQ coupled with LC-MS/MS method.

  UniProt accession   Gene symbol   Name                                                                         Unique peptides   CUMS/CON   t-test P-value
  ------------------- ------------- ---------------------------------------------------------------------------- ----------------- ---------- ----------------
  Q6LD55              APOA2         APOAII                                                                         2               0.23       1.19E-03
  A2APX3              CST3          Cystatin-C (Fragment)                                                          2               0.44       3.28E-02
  Q9EQI5              PPBP          Chemokine (C-X-C motif) ligand 7, isoform CRA_b                                2               0.6        5.08E-03
  P98086              C1QA          Complement C1q subcomponent subunit A                                          2               0.61       7.75E-04
  O55222              ILK           Integrin-linked protein kinase                                                 2               0.64       8.66E-03
  P23492              PNP           Purine nucleoside phosphorylase                                                2               0.65       7.82E-03
  Q8CAG6              PLEK          Pleckstrin                                                                     2               0.65       9.63E-03
  Q5FW60              MUP20         Major urinary protein 20                                                       2               0.66       7.91E-03
  Q8BPF4              N/A           Putative uncharacterized protein                                               3               0.67       1.69E-02
  A2AQ07              TUBB1         Tubulin β-1 chain                                                              2               0.67       6.90E-04
  P14106              C1QB          Complement C1q subcomponent subunit B                                          5               0.69       3.03E-04
  P07310              CKM           Creatine kinase M-type                                                         4               0.7        1.86E-02
  Q02105              C1QC          Complement C1q subcomponent subunit C                                          4               0.7        7.42E-03
  A7LNR1              CD93          CD93 antigen (Fragment)                                                        2               0.7        2.26E-02
  D3Z0Y2              PRDX6         Peroxiredoxin-6                                                                3               0.71       8.35E-03
  A2AE89              GSTM1         Glutathione S-transferase Mu 1 (Fragment)                                      2               0.71       8.21E-03
  Q8K0E8              FGB           Fibrinogen β chain                                                           32                0.71       2.34E-03
  P26039              TLN1          Talin-1                                                                      19                0.72       2.10E-03
  Q923D2              BLVRB         Flavin reductase (NADPH)                                                       6               0.72       4.08E-03
  P13634              CA1           Carbonic anhydrase 1                                                           4               0.72       3.71E-03
  P16015              CA3           Carbonic anhydrase 3                                                           3               0.74       3.81E-02
  B1AXY5              B4GALT1       β-1,4-galactosyltransferase 1                                                  2               0.75       1.74E-02
  P61089              UBE2N         Ubiquitin-conjugating enzyme E2 N                                              3               0.75       1.09E-02
  P32848              PVALB         Parvalbumin α                                                                  3               0.75       2.21E-02
  P97336              OBP1A         Odorant binding protein Ia (Fragment)                                          4               0.76       7.95E-04
  P06909              CFH           Complement factor H                                                          46                1.31       9.61E-03
  P31532              SAA4          Serum amyloid A-4 protein                                                      7               1.32       7.37E-03
  B2RXW7              C4B           Complement component 4B (Childo blood group)                                 64                1.33       7.25E-03
  A1L3C5              PRG4          Prg4 protein                                                                   4               1.34       4.24E-02
  P01027              C3            Complement C3                                                                107               1.34       5.16E-03
  Q71KU9              FGL1          Fibrinogen-like protein 1                                                      3               1.35       3.33E-03
  G3X8T9              SERPINA3N     Serine (Or cysteine) peptidase inhibitor, clade A, member 3N,isoform CRA_a   18                1.37       2.41E-04
  Q03734              SERPINA3M     Serine protease inhibitor A3M                                                  7               1.39       2.97E-03
  Q8BJU6              COL3A1        Putative uncharacterized protein (Fragment)                                    3               1.39       4.46E-02
  Q8VCM7              FGG           Fibrinogen gamma chain                                                       31                1.41       5.87E-03
  Q9D8W4              IGLV1         β-2-microglobulin                                                              2               1.41       5.42E-03
  E9PV24              FGA           Fibrinogen α chain                                                           37                1.41       2.95E-03
  Q61805              LBP           Lipopolysaccharide- binding protein                                            4               1.42       1.40E-02
  Q91X72              HPX           Hemopexin                                                                    25                1.53       5.85E-04
  Q61704              ITIH3         Inter-α-trypsin inhibitor heavy chain H3                                     19                1.6        2.74E-03
  P61939              SERPINA7      Thyroxine-binding globulin                                                   12                1.61       4.15E-03
  Q60590              ORM1          α-1-acid glycoprotein 1                                                        6               1.62       1.81E-03
  Q91XL1              LRG1          Leucine-rich HEV glycoprotein                                                  6               1.74       5.48E-03
  P12246              APCS          Serum amyloid P-component                                                      6               1.87       3.58E-03
  P07361              ORM2          α-1-acid glycoprotein 2                                                        3               2.5        1.14E-04
  Q00898              SERPINA1E     α-1-antitrypsin 1--5                                                           4               2.51       4.08E-03
  Q61646              HP            Haptoglobin                                                                  18                2.98       9.14E-04

CUMS, chronic unpredictable mild stress; CON, control; iTRAQ, isobaric tag for relative and absolute quantitation.

###### 

Significant differentially changed pathways and related proteins.

  Ingenuity canonical pathways                                                   P-value      Molecules
  ------------------------------------------------------------------------------ ------------ --------------------------------------------------------------------------------------------
  Acute phase response signaling                                                 1.00x^−19^   HPX, ITIH3, C3, APOA2, SERPINA3, SAA2-SAA4, FGG, C4A/C4B, HP, APCS, SERPINA, FGB, LBP, FGA
  Complement system                                                              1.00x^−10^   C4A/C4B, C3, C1QA, C1QC, CFH, C1QB
  LXR/RXR activation                                                             3.72x−^09^   C4A/C4B, HPX, C3, APOA2, SERPINA1, LBP, FGA
  FXR/RXR activation                                                             1.70x^−07^   C4A/C4B, HPX, C3, APOA2, SERPINA1, FGA
  Intrinsic prothrombin activation pathway                                       3.02x^−07^   FGB, FGA, FGG, COL3A1
  Coagulation system                                                             6.61x^−07^   SERPINA1, FGB, FGA, FGG
  Extrinsic prothrombin activation pathway                                       3.98x^−06^   FGB, FGA, FGG
  Role of pattern recognition receptors in recognition of bacteria and viruses   1.51x^−04^   C3, C1QA, C1QC, C1QB
  Role of tissue factor in cancer                                                1.82x^−03^   FGB, FGA, FGG
  Xanthine and xanthosine salvage                                                2.00x^−03^   PNP
  Atherosclerosis signaling                                                      2.04x^−03^   APOA2, SERPINA1, COL3A1
  Guanine and guanosine salvage I                                                3.98x^−03^   PNP
  Adenine and adenosine salvage I                                                3.98x^−03^   PNP
  Arsenate detoxification I (Glutaredoxin)                                       7.94x^−03^   PNP
  Heme degradation                                                               7.94x^−03^   BLVRB
  IL-10 signaling                                                                7.94x^−03^   BLVRB, LBP
  Creatinx-phosphate biosynthesis                                                9.77x^−03^   CKM
  Adenine and adenosine salvage III                                              1.38x^−02^   PNP
  Purine ribonucleosides degradation to ribosx-1-phosphate                       1.58x^−02^   PNP
  TR/RXR activation                                                              1.62x^−02^   HP, FGA
  Guanosine nucleotides degradation III                                          2.51x^−02^   PNP
  Urate biosynthesis/inosine 5′-phosphate degradation                            2.75x^−02^   PNP
  Glutaryl-CoA degradation                                                       2.95x^−02^   CA1
  Phagosome maturation                                                           3.31x^−02^   TUBB1, PRDX6
  Adenosine nucleotides degradation II                                           3.31x^−02^   PNP
  IL-12 signaling and production in macrophages                                  3.39x^−02^   APOA2, SERPINA1
  Purine nucleotides degradation II (Aerobic)                                    3.89x^−02^   PNP
  Germ cell-sertoli cell junction signaling                                      4.57x^−02^   TUBB1, ILK
  Glutathione redox reactions I                                                  4.68x^−02^   PRDX6
  Tryptophan degradation III (Eukaryotic)                                        4.68x^−02^   CA1
  Sertoli cell-sertoli cell junction signaling                                   4.79x^−02^   TUBB1, ILK

P-value: Fisher\'s exact test; Molecules: The uploaded proteins mapped to the pathway.

###### 

Significant differentially changed diseases and functions with uploaded proteins (top 10).

  Category                                        P-value                 Molecules
  ----------------------------------------------- ----------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Developmental disorder                          1.43x^−10^−3.95x^−03^   TUBB1, C3, ILK, C1QA, C1QC, HBA1/HBA2, C1QB, SERPINA7, FGG, C4A/C4B, CA3, HP, B4GALT1, CST3, APCS, PNP, SERPINA1, FGB, FGA, CA1, COL3A1
  Hereditary disorder                             1.43x^−10^−3.95x^−03^   APOA2, LRG1, C1QA, SERPINA3, C1QC, HBA1/HBA2, C1QB, SERPINA7, PRDX6, FGG, C4A/C4B, CA3, CST3, APCS, FGB, SERPINA1, CFH, CA1, TUBB1, PVALB, C3, HP, B4GALT1, PNP, FGA, COL3A1
  Immunological disease                           1.43x^−10^−3.95x^−03^   TUBB1, HPX, C3, C1QA, C1QC, HBA1/HBA2, C1QB, PRDX6, FGG, C4A/C4B, CA3, HP, B4GALT1, CST3, APCS, PNP, SERPINA1, FGB, PLEK, LBP, CFH, FGA, CA1, COL3A1
  Organismal injury and abnormalities             1.43x^−10^−3.95x^−03^   ITIH3, GSTM5, UBE2N, APOA2, LRG1, ILK, C1QC, TLN1, SERPINA3, C1QA, HBA1/HBA2, C1QB, SERPINA7, PRDX6, FGG, C4A/C4B, CA3, APCS, CST3, SERPINA1, FGB, LBP, CFH, CA1, PVALB, TUBB1, HPX, C3, CKM, CD93, BLVRB, HP, B4GALT1, PNP, FGL1, PLEK, FGA, COL3A1
  Cell-To-cell signaling and interaction          6.08x^−10^−3.95x^−03^   C3, Ppbp, UBE2N, APOA2, CD93, ILK, C1QA, TLN1, FGG, C4A/ C4B, B4GALT1, APCS, CST3, PNP, FGB, SERPINA1, PLEK, LBP, CFH, FGA, COL3A1
  Hematological system development and function   6.08x^−10^−3.95x^−03^   UBE2N, APOA2, ILK, C1QC, TLN1, SERPINA3, C1QA, HBA1/ HBA2, FGG, C4A/C4B, APCS, CST3, FGB, SERPINA1, CFH, LBP, HPX, C3, Ppbp, CD93, HP, B4GALT1, PNP, PLEK, FGA
  Immune cell trafficking                         6.08x^−10^−3.95x^−03^   C3, Ppbp, UBE2N, CD93, ILK, C1QA, TLN1, SERPINA3, FGG, C4A/C4B, HP, B4GALT1, CST3, APCS, FGB, SERPINA1, CFH, LBP, FGA
  Inflammatory response                           7.5x^−10^−3.95x^−03^    TUBB1, HPX, C3, CKM, APOA2, UBE2N, CD93, ILK, SERPINA3, TLN1, C1QA, HBA1/HBA2, PRDX6, FGG, C4A/C4B, CA3, HP, B4GALT1, APCS, CST3, PNP, SERPINA1, FGB, PLEK, CFH, LBP, FGA, CA1, COL3A1
  Cellular movement                               6.12x^−09^−3.95x^−03^   C3, Ppbp, CD93, ILK, TLN1, SERPINA3, PRDX6, C4A/C4B, HP, B4GALT1, APCS, CST3, SERPINA1, FGB, CFH, LBP, FGA, COL3A1
  Hematological disease                           7.18x^−09^−3.95x^−03^   TUBB1, C3, CKM, APOA2, CD93, C1QA, HBA1/HBA2, FGG, C4A/C4B, HP, SERPINA1, FGB, FGL1, LBP, PLEK, CFH, FGA

P-value: Fisher\'s exact test; Molecules: The uploaded proteins mapped to relevant diseases and functions. The uploaded proteins involved in the Cell-To-Cell Signaling and Interaction are shown in [Fig. 3](#f3-mmr-17-01-0093){ref-type="fig"} produced by IPA.

[^1]: Contributed equally
